FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy
Porosome Therapeutics, Inc. enters a new frontier in secretory defect therapeutics through porosome reconstitution
BOSTON--(BUSINESS WIRE)--Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA).